CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [11]

Active Indication

InflammationLocalized Prostate CarcinomaAdenocarcinoma of prostate+ [38]

Inactive Indication

Aberrant Crypt FociAdvanced cancerColitis, Ulcerative+ [5]

Originator Organization

The University of Texas MD Anderson Cancer Center

Active Organization

Seoul National UniversityFranklin Square Hospital Center, Inc.

The Ohio State University

+ [44]

Inactive Organization

3i Nature SAS

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Genzada Pharmaceuticals Usa, Inc.

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC21H20O6

InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N

CAS Registry458-37-7

654

Clinical Trials associated with Curcumin

CTRI/2024/11/076875

/ Not yet recruitingPhase 4

A Single Center, Randomized, Double blind, Placebo Controlled Pilot Study to Evaluate the Efficacy, Safety and Tolerability of Turmeric Lemonade Energy Drink (Bioactive Curcumin Plus Green Tea Plus Ginger Plus Lemon Plus Lime) manufactured by Golden Tiger Life Corp in the Treatment of Patients with Moderate Osteoarthritis of Knee. - Nil

Start Date06 Nov 2025

Sponsor / Collaborator

Tiger Companies

NCT06478290

/ Not yet recruitingNot Applicable

Pilot Assessment of the Safety of a Combination of Curcumin, Omega-3, and Vitamin D Supplements (PASCOD) in ACPA+ Individuals

The goal of this clinical trial is to determine if the level of Anti-cyclic citrullinated peptide antibody (ACPA) is altered after taking curcumin, omega-3, and vitamin D supplements (COD) for 3 months. It will also determine the safety and tolerability of COD in the study population. This trial aims to answer the following questions: Does COD consumption lower the level of ACPA in the study participants? What side effects will participants have after taking COD? This pilot study will have an open label pre-post design and study participants will know that they are using each of the three supplements. Participants will: Take the combination of supplements following an evening meal, for 84 consecutive days. Visit the clinic/study team twice during the study duration on days 0 and 84 for checkups and tests. Keep a diary of study treatment consumption.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Manitoba

[+1]

CTRI/2025/06/088964

/ Not yet recruitingNot ApplicableIIT

Clinical effectiveness of a Curcumin-Based Functional Phytotherapeutic Oral Delivery System in Modulating Gingival Inflammation and Oral Hygiene Parameters among Adults: A Non-Randomized, Prospective Single-Arm Interventional Study - NIL

Start Date21 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Curcumin

100 Translational Medicine associated with Curcumin

100 Patents (Medical) associated with Curcumin

31,102

Literatures (Medical) associated with Curcumin

01 Apr 2026·BIOMATERIALS

Dual-release 3D-printed porous Ti–6Al–4V implant with drug-eluting photothermal micro-nanotopographies: combating osteosarcoma recurrence, infections, and enhancing osteogenesis

Article

Author: Liang, Xichang ; Liu, Peilai ; Ji, Zhenbing ; Zou, Yujin ; Wan, Yi ; Wang, Hongwei

3D-printed porous Ti-6Al-4V implants are widely used in bone defect repair following osteosarcoma resection due to their favorable mechanical properties and biocompatibility. However, eliminating residual tumor cells, preventing bacterial infection, and ensuring effective osseointegration remain key challenges. In this paper, the implant containing a dual-release system was developed. First, a primary drug reservoir was constructed using nanotubes loaded with ZnO and rare earth elements (Y, Yb, Er). Second, a secondary phototherapy platform was created by coating the reservoir with a gelatin/sodium alginate hydrogel containing MgO₂, curcumin, and paclitaxel. Flow acid etching and anodic oxidation removed residuals and formed TiO₂ nanotube arrays, while rare earth doping enhanced upconversion capability. Under 808 nm near-infrared irradiation (NIR), localized photothermal heating (54 °C) triggered hydrogel degradation, releasing the contents. Subsequently, the primary reservoir facilitated sustained Zn²⁺ release alongside micro-nano cues. The modified surface demonstrated improved wettability and superior corrosion resistance. Meanwhile, the hydrogel exhibited near-complete degradation (95 %) within 21 days, corresponding to the optimal therapeutic window following tumor resection. The biological experiments demonstrated that the dual-release system systematically inhibited tumor growth, eradicated bacterial infections, and promoted osteogenesis. Furthermore, this system modulated intracellular signaling pathways in both bone marrow mesenchymal stem cells (MSCs) and osteosarcoma cells (HOS). The system orchestrated metabolic reprogramming and modulated organelle dynamics. These coordinated effects simultaneously enhanced MSCs' osteogenic differentiation while inducing apoptosis in HOS. Furthermore, the system potentiated reactive oxygen species (ROS) production, amplifying oxidative stress in bacterial populations. This strategy presents a therapeutic approach for post-resection osteosarcoma management.

01 Apr 2026·BIOMATERIALS

Framework nucleic acid-based hydrogel for sequential immune regulation and endogenous TGF-β1 capture in wound healing

Article

Author: Bai, Long ; Cai, Xiaoxiao ; Yue, Ziqi ; Chen, Xingyu ; Lin, Yunfeng ; Yin, Wumeng ; Yang, Yichen ; Wang, Ruiqing

Wound healing is a highly coordinated process that requires timely resolution of inflammation in the early phase and localized activation of regenerative signals during tissue remodeling. Disruption of this sequential regulation often leads to impaired epithelial regeneration and fibrotic remodeling. Transforming growth factor-β1 (TGF-β1) plays a pivotal role in fibroblast activation and extracellular matrix (ECM) synthesis, yet exogenous delivery is limited by instability, off-target effects and fibrotic scarring risk. To address these challenges, we developed a sequential immune-regenerative strategy, in which early anti-inflammatory modulation is followed by localized enrichment of endogenous regenerative cues. β-peptides with high binding affinity to TGF-β1 were trivalently presented on a tetrahedral framework nucleic acid (tFNA) to enable efficient cytokine capture (over 90 % efficiency), while curcumin was incorporated to provide early-phase immunoregulation by suppressing NF-κB signaling, thereby creating a permissive environment for subsequent remodeling. These dual functions were combined in a β3Tc nanostructure, which was subsequently incorporated into a hyaluronic acid methacryloyl (HAMA) scaffold to form a composite hydrogel (HA-β3Tc). The hydrogel demonstrated excellent physicochemical properties, biocompatibility, and bioactivity. In a full-thickness wound model, HA-β3Tc accelerated wound closure, enhanced fibroblast differentiation, and mitigated scar formation. Collectively, this study presents a synergistic immune-regenerative hydrogel platform that combines sequential early anti-inflammation with late-phase spatial TGF-β1 capture, offering a promising strategy for effective and safe tissue repair.

01 Feb 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Deciphering synergistic interactions between Curcumin, Piperine, and milk proteins using accurate theoretical methods

Article

Author: Krishnamoorthy, Gayathri ; Ravindran, Vidya ; Palanisamy, Madhesh

This work focuses on studying the interaction between the active biomolecules found in turmeric and pepper with key milk proteins, which is a popularly adopted in the Siddha, one of the Indian Traditional Medicinal Systems, to treat cold and throat-related illnesses. Curcumin and Piperine are the active biomolecules in turmeric and pepper, respectively. Hence, we have analyzed their interaction with key milk proteins such as Bovine Serum Albumin (BSA), Lactaglobulin, and Lactalbumin. The interactions were computationally investigated to elucidate the underlying mechanism behind the efficacy of the aforementioned formulation using accurate first-principle calculations based on Density Functional Theory (DFT) and Molecular Docking simulations. The formation of the Curcumin-Piperine (CP) complex, as well as its binding with milk proteins, was evaluated using computational techniques. We have predicted the allosteric sites of the milk proteins and investigated the allosteric regulation effect in these proteins by Curcumin and Piperine. The results revealed the formation and increased bioactivity of the drug complex, thereby providing a molecular basis for the observed synergistic efficacy of this traditional formulation.

News (Medical) associated with Curcumin

13 Oct 2025

·www.prnewswire.com

Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health

XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This technology demonstrates strong potential in enhancing the bioavailability, stability, and synergistic effects of active ingredients, opening up new pathways for health support. Continue Reading Co-loaded Liposomes Show Enhanced Cardiovascular Support — Both CoQ10 and Curcumin liposomes demonstrated superior improvement compared to their conventional forms under experimental conditions. During this R&D process, Natural Field conducted in-depth exploration into the mechanisms of action and efficacy of co-loading CoQ10 liposomes and co-loading curcumin liposomes in areas such as cardiovascular function and gut health. Experimental data shows that the bioabsorption rate of these two co-loading liposomes is 2-10 times higher than that of traditional raw materials. These preliminary data indicate that NFLipo® has more competitive performance in cardiovascular protection, antioxidant, anti-inflammatory, and intestinal barrier regulation. This technological breakthrough brings the following advantages: Higher Bioavailability: Through structural optimization of co-loading liposomes, multiple functional ingredients can be synergistically packaged and stably delivered to target sites more efficiently. Improved Stability: Ordinary liposomes still rely on cellular uptake after extracellular release, which is easily limited by P-glycoprotein (P-gp) efflux, resulting in insufficient intracellular entry efficiency. The new co-loading liposome technology can not only effectively bypass this efflux pathway but also inhibit its activity, thereby significantly improving the bioavailability of ingredients and enhancing their stability during storage and in-vivo transportation. Synergistic Efficacy Potential: The combination of rare ginsenosides with CoQ10 and curcumin not only enhances membrane stability but also co-loads more active ingredients. For example, it meets the synergistic effects of antioxidant support and anti-aging skin care, expanding the functional dimensions of products. Enhanced Customized Development Capabilities: Natural Field has launched a "one-stop liposome service" model, providing customers with personalized customization solutions covering formula design, process optimization, quality control, and large-scale production. As a 20-year supplier in the nutritional health raw material sector, Natural Field has always emphasized both technological innovation and standardized compliance. Currently, its official website clearly lists "co-loading liposomes" as a key product category, and the company has repeatedly highlighted the technology's patent potential and application scenarios in exhibition promotions. To promote industry exchanges and application implementation, Natural Field will participate in the SupplySide Global Exhibition in the U.S. in October 2025, Booth No.6247. At the exhibition, it will showcase its latest co-loading liposome platform and sample products, and conduct in-depth dialogues with global nutritional health raw material suppliers, health supplement manufacturers, and research institutions to explore cooperation opportunities for liposomes in nutritional support and functional raw materials. Through this technological showcase, Natural Field aims to further establish its leading position in the liposome and co-loaded liposome technology field in the international market, provide customers with more efficient, safer, and more differentiated raw material solutions, and drive the entire nutritional health industry toward a higher technological threshold and value chain level. SOURCE Natural Field WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

29 Sep 2025

·www.prnewswire.com

Vascarta Announces Completion of Phase 1 Clinical Trial of VAS-101 for the Treatment of Osteoarthritis

SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the treatment of osteoarthritis (OA). The study was conducted at Clinical Research Australia in Perth under the direction of Principal Investigator Dr. Adrian Lopresti. Publication and/or presentation of the data is expected in the coming months. The 60-patient, randomized, double-blind, placebo-controlled trial evaluated VAS-101, a proprietary curcumin gel, applied topically every other day for 28 days. The primary objective was to assess the effects of VAS-101 on pain in adults with chronic knee OA. Secondary objectives included evaluating the therapy's impact on safety and tolerability, quality of life, daily function, and the use of analgesics. Dr. Lopresti commented: "When taken orally, curcumin is limited by low absorption, which reduces its therapeutic potential. In this study, VAS-101 administered topically demonstrated promising pain-relieving effects in people with knee osteoarthritis. These findings suggest that Vascarta's Vasporta™ transdermal technology may overcome the bioavailability challenges of oral curcumin, enabling rapid, localized pain relief at much lower doses." About VAS-101 Curcumin is a well-known natural compound with anti-inflammatory and analgesic properties, but its clinical utility has been constrained by poor oral bioavailability. VAS-101 is a highly concentrated, patented curcumin gel formulated using Vascarta's proprietary Vasporta™ transdermal delivery platform, designed to enhance both local and systemic bioavailability. Unmet Need in Knee Osteoarthritis According to the U.S. Centers for Disease Control and Prevention, approximately 21% of U.S. adults were diagnosed with arthritis between 2019 and 2021, with the knee being the most affected joint (World Health Organization). Current treatment options often progress from oral medications to invasive interventions such as intra-articular corticosteroids, hyaluronic acid, platelet-rich plasma, or ultimately, surgical knee replacement. There remains a significant unmet need for non-invasive, effective, and well-tolerated therapies that can provide pain relief for patients, particularly those who cannot tolerate long-term NSAID use. Leadership Perspective "Osteoarthritis is one of the most prevalent and disabling chronic conditions," said Dr. Richard Prince, Vascarta Chairman, CEO & President. "The completion of this Phase 1 trial marks an important milestone in the development of VAS-101 and supports our vision to deliver a safer, effective, and non-invasive alternative for millions of patients worldwide." About Vascarta Vascarta is a clinical-stage pharmaceutical company focused on innovative topical and transdermal delivery of therapeutics for inflammatory conditions, with lead programs in osteoarthritis and sickle cell disease. For more information about Vascarta's clinical programs, please contact: Dr. Richard Prince, Chairman, CEO & President – [email protected] Media Inquiries: David Hymson – [email protected] SOURCE Vascarta Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1

11 Aug 2025

·www.globenewswire.com

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today introduced Nugevia™ MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. MND addresses the surging consumer demand for clinically validated cognitive wellness solutions, opening up significant market opportunities in the rapidly growing $8 trillion longevity and wellness markets. Innovative CNS Science, Dual-Purpose Potential Nugevia MND uniquely combines Jupiter’s proprietary JOTROL™ resveratrol technology—demonstrated to significantly improve bioavailability and central nervous system penetration—with NovaSOL® Curcumin, a highly bioavailable curcumin formulation proven effective in supporting cognitive resilience and neuroprotection. This innovative pairing targets multiple neuroprotective pathways, including reducing oxidative stress, inflammation, and supporting synaptic plasticity, thereby promoting enhanced cognitive health. "We’ve worked extensively on our third, and in my opinion the most important, product in the Nugevia™ launch. It is my pleasure to introduce MND to the healthspan and longevity community,” stated Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease. This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical date we are here to bring what we believe is the best cognition product to the market.” “The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market,” added Rosén. “Importantly, learnings from consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs. What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.” Strategic Insight, Expanded Potential Nugevia MND is poised to generate high-margin revenue by targeting adults seeking to maintain and enhance cognitive performance, particularly amidst aging populations increasingly impacted by cognitive decline. The product also strategically complements Jupiter’s therapeutic pipeline, creating synergies between consumer and pharmaceutical segments. Key scientifically supported benefits of Nugevia MND include: Enhanced memory, clarity, and executive functionReduction in neuroinflammation and oxidative stressSupport for mitochondrial function in brain cellsPotential protective effects against age-related cognitive decline "MND not only reinforces our dual-path business strategy but also provides an immediate opportunity for revenue growth and meaningful data collection," continued Rosén. "Investors can be excited about the implications of a consumer product directly supporting our pharmaceutical development pipeline." Nugevia MND will be commercially available through direct-to-consumer e-commerce platforms starting Fall 2025 as a convenient two-capsule daily regimen. A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease. In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@redchip.com

Phase 2Phase 1

100 Deals associated with Curcumin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Curcumin	-	DB11672

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Localized Prostate Carcinoma	Phase 3	United States	The University of Texas Southwestern Medical Center	11 Mar 2019
Crohn Disease	Phase 3	France	3i Nature SAS	01 Dec 2014
Adenocarcinoma of prostate	Phase 3	United States	The University of Texas Southwestern Medical Center	01 May 2014
Colorectal Cancer	Phase 3	-	University of Pennsylvania	-
Colorectal Cancer	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	University of Pennsylvania	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	University of Pennsylvania	-
Stomatitis	Phase 3	-	University of Pennsylvania	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2024	Not Applicable	Osteoarthritis	106	Supplement combination	skcfwvyhab(abguzwppop) = mhxsgfggkj ltfzeljnsx (wkrfhxfqdb, -14.35 to -2.92)	Negative	10 Nov 2024
				Placebo	skcfwvyhab(abguzwppop) = ytxsytmsiu ltfzeljnsx (wkrfhxfqdb, -20.94 to -8.32)
NCT02944578 (CTgov)	Phase 2	Uterine Cervical Dysplasia \| Cervical Intraepithelial Neoplasia	7	Curcumin (Curcumin)	cqgnxzgsfr = zygnqqvgya dymdrvjyif (ioubkpkdxg, fcemwvarry - egcotvnzrv) View more	-	29 Oct 2024
				placebo (Placebo)	cqgnxzgsfr = zedftdxxsv dymdrvjyif (ioubkpkdxg, tqvddlkixi - bsnwoaqenp) View more
NCT03223883 (CTgov)	Phase 2	Cognitive Dysfunction \| Chronic Kidney Diseases	94	Curcumin (Curcumin)	eqylfmzdad(snljhailod) = sehefiqkti bhqjziragh (naslrwbpuo, bogdrlqnmp - iehvkamhgr) View more	-	08 Oct 2024
				Placebo (Placebo)	eqylfmzdad(snljhailod) = ewrguqvudx bhqjziragh (naslrwbpuo, dvjibzxusu - bvyeqsytap) View more
NCT04205929 (CTgov)	Phase 4	Hemorrhage \| Metrorrhagia	58	Placebo (Placebo Group)	rbrlluwuzd(filprkvyvk) = xvynqyowgp ugwcnpvfrc (bbqaussjem, 4.8) View more	-	03 Jul 2024
				Curcumin (Curcumin Group)	rbrlluwuzd(filprkvyvk) = drmezhztyw ugwcnpvfrc (bbqaussjem, 6.9) View more
NCT02100423 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| B-Cell Lymphoma \| Small Lymphocytic Lymphoma	35	pharmacological study+cholecalciferol+Curcumin	jxnixpxmvu = mxaskzmwes zugfbofwby (vjkfekfakt, yotooedqcz - mfmmevjmpv) View more	-	12 Apr 2024
NCT02782949 (CTgov)	Phase 2	Carcinogenesis \| Gastritis, Atrophic \| Stomach Cancer	50	Quality-of-Life Assessment+Curcumin (Arm I (Curcumin))	xseslidjxp(axduqdfhav) = skuhkkieqk txxfbdmuwk (dzuqynkkyv, xirypwjhgi - ishxacmdrn) View more	-	05 Mar 2024
				Quality-of-Life Assessment (Arm II (Placebo))	xseslidjxp(axduqdfhav) = hfdjkeyptu txxfbdmuwk (dzuqynkkyv, hprenabjfa - vjupajdcwh) View more
NCT02494141 (CTgov)	Phase 4	Polycystic Kidney, Autosomal Dominant \| Ischemic Attack, Transient	68	Curcumin (Curcumin)	izvccrmjqw(rdnuozgylj) = icveekeisu gfijtodjak (vrfcmhrclg, bmbilhgvaw - hgkxlljmgk) View more	-	03 Mar 2022
				Placebo (Placebo)	izvccrmjqw(rdnuozgylj) = eqavknlrrc gfijtodjak (vrfcmhrclg, yjktznbska - svmefobjzo) View more
NCT03085680 (SPICE, CTgov)	Phase 2/3	Cognition	17	Curcumin (Curcumin)	aypnkxpesr(tqdrrmduyo) = liuzgyhbzv wjuauephtg (rwemjkacym, 0.090) View more	-	02 Feb 2022
				microcrystalline cellulose (Placebo)	aypnkxpesr(tqdrrmduyo) = sjudglmjnr wjuauephtg (rwemjkacym, 0.10) View more
IRCT20191112045424N1 \| NCT05430087 (Pubmed \| BMC Complement Med Ther)	Phase 2/3	Dysmenorrhea \| Premenstrual Syndrome	76	Curcumin	ujsyuqypxl(ewjamjptlk) = nrtnxohwji ttmmwcxkue (ppbxbgewgw, 7.0 - 24.6)	Positive	22 Jan 2022
				Curcumin (Placebo)	ujsyuqypxl(ewjamjptlk) = jvbwzawbue ttmmwcxkue (ppbxbgewgw, 5.2 - 27.1)
NCT02494141 (Pubmed \| Clin J Am Soc Nephrol)	Phase 4	Polycystic Kidney, Autosomal Dominant	68	Curcumin supplementation	hvlqmyeldz(jjftrsjvdc) = fgcqcumldy smsctsqqem (uslldswpwh ) View more	Negative	14 Dec 2021
				Placebo	hvlqmyeldz(jjftrsjvdc) = vrjvaytgmp smsctsqqem (uslldswpwh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Curcumin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation